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Introduction
Wolfram syndrome (WS; OMIM 222300) was first described by 
Wolfram and Wagener as the association of childhood-onset Diabetes 
Mellitus (DM) and Optic Atrophy (OA). The disorder is also known 
with the acronym DI-DM-OA-D, since additional clinical features 
observed in the majority of patients include Diabetes Insipidus 
(DI) and sensori neuronal deafness at high-frequency (D). It is a 
progressive neurodegenerative disorder, possibly developing ataxia, 
peripheral neuropathy, and psychiatric illness. Non autoimmune, 
non HLA-linked diabetes mellitus develops in the first decade of 
life, at a median age of 6 years, and usually administration of insulin 
is required. Other complications include urogenital anomalies, and 
less frequent complications such as gastrointestinal anomalies, most 
often dysmotility and/or chronic diarrhoea. Primary gonadal atrophy 
is common in males, and many females have menstrual irregularity 
and delayed menarche [2,3]. Follow-up studies demonstrate that 
WS patients could develop all symptoms if they live long enough. 
Death occurs prematurely, with a median age of 30 years, often from 
respiratory failure caused by brain stem atrophy. The prevalence of WS 
was estimated as 1/770,000 in the UK, with a carrier frequency of 1 in 
354; and 1/100,000 in the North American population, based on the 
1/175 occurrence of optic atrophy in a juvenile-diabetes clinic.
The WFS1 gene (MIM# 606201) maps to chromosome 4p16, and 
consists of eight exons, encompassing 33.4 kb of genomic DNA: exon 
1 is noncoding, exons 2-7 are small coding exons and the largest exon, 
exon 8, is 2.6 kb long. Most patients carry mutations in the WFS1 
gene; a second form of WS is caused by a homozygous mutation in 
a recently identified zinc-finger protein, Endoplasmatic Reticulum 
Intermembrane Small protein (ERIS) encoded by the WFS2 gene, 
mapping to 4q22-q25 [4-7]. Defects in mitochondrial DNA were 
reported in some sporadic cases, but the mitochondrial genome was 
not found to be systematically involved in the disease [8-11]. Mutations 
reported in the WFS1 gene give rise to two distinct phenotypes: 
autosomal recessive WS and autosomal dominant low-frequency 
sensorineural hearing loss (AD LFSNHL) [5,12].
The WFS1 gene transcribes a 3.6 kb mRNA that encodes 
Wolframin, a 890-amino-acid protein, abundantly detected in the adult 
human heart, brain, placenta, lung, and pancreas beta-cells [3,5,6]. 
Wolframin is a calmodulin glycoprotein resident in the membrane of 
the Endoplasmic Reticulum (ER) involved in the ER stress signalling 
[3,13]. It has been speculated that in WS patients a dysregulation of the 
ER stress signalling could lead to cell death in the affected cells such as 
pancreatic beta-cells or neurons [3,13].
Mutations associated with the disease phenotype are distributed 
along the entire gene, with homozygous and compound heterozygous 
genotypes. To date, over 200 distinct mutations in WFS1 have been 
identified in WS individuals from different ethnic backgrounds, and 
these include a variety of missense, nonsense, and frameshift insertion/
deletion mutations [3,5,6,13-22]. 
Cognitive impairment seems to be more frequent than how much 
estimated in the past, and epilepsy is  diffuse in the children with an 
early onset of neurological signs, associated with malformations 
of cortical development with white matter involvement, including 
leukoencephalopathy 
The majority of patients with DIDMOAD carry mutations that 
presumably result in a loss of function of Wolframin. This suggests that 
a lack of Wolframin protein is the disease-causing agent [3,5,6,13-18].
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Abstract
Wolfram Syndrome (WS) is a rare hereditary disease with autosomal recessive inheritance with incomplete 
penetrance. It is characterized by diabetes mellitus associated with progressive optic atrophy. The diagnosis is 
essentially clinical and mutation analysis is used to confirm the diagnosis. In the present study we describe the 
clinical and molecular features of a diabetic child carrying two novel WFS1 mutations. The Sicilian proband and his 
non-affected family were studied. Ophthalmologic examination included: visual acuity determination and funduscopy, 
optical coherent tomography, retinal fluorangiography, perimetry and electroretinogram. Molecular methods: 
automatic sequencing of PCR amplified WFS1 gene fragments and qRT-PCR analysis of WFS1 transcripts. 3 WSF1 
mutations have been identified in the proband. One allele carries 2 paternally inherited mutations (c.1332 C>G and 
c.1631C>G) in exon-8, never annotated before, in heterozygosis with one “de novo” classic mutation (c.505 G>A) in 
exon-5. In addition, we report an unexpected molecular feature: higher WFS1 mRNA levels in the proband compared 
to the father.
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Milan, Italy) following manifacturer’s instructions. A neuroblastoma 
cell line (LAN5) used as a positive control. WFS1 expression was 
analysed by real-time quantitative RT-PCR (qRT-PCR) in individual 
samples and WFS1 mRNA levels were quantified in comparison 
to β-actin mRNA expression. WFS1 PCR primers were purchased 
from Quiagen (Quantitect Primer Hs_WFS1_1_SG QT00082663) 
the amplicon size was 117 bp (Suppl. Figure 1); β-actin primers were 
obtained from RealTimePrimers.com (Elkins Park, PA, USA) with 
the following sequences: F 5’-GGACTTCGAGCAAGAGATGG-3’; 
R 5’-AGCACTGTGTTGGCGTACAG-3’; the amplicon size was 
234 bp. All reactions were performed using the LightCycler 1.0 
(Roche Diagnostics GMbH, Germany). Briefly, 2 g of total RNA was 
retrotranscribed using the ImProm-II™ Reverse Transcription System 
(Promega, Milan, Italy). Each RNA was combined with 1l of oligo-
16dT (Promega Milan, Italy) and thermally denatured at 70°C for 5 
minutes and then chilled on ice. As a final step, the template-oligo-
dT combination was added to the reaction mix (4 l ImProm-II™ 1X 
Reaction Buffer, 1l ImProm-II™ Reverse Transcriptase, 3.2 l Magnesium 
Chloride 3 mM, 1 l dNTPs mix 10 mM and 1 l Recombinant RNasin 
Ribonuclease Inhibitor 1u/l) and nuclease-free water was added to 20 
l of final volume on ice. Following an initial annealing at 25°C for 5 
minutes, the reaction was incubated at 42°C for one hour. In order to 
heat-inactivate the ImProm-II Reverse Transcriptase the reaction mix 
was finally incubated at 70°C for 15 minutes. 
Real-time PCR was performed using 2 l of cDNA diluited 1:5, 
plus 10 l of Quantitech master mix (Qiagen), 2 l of  Quantitect Primer 
Hs_WFS1_1_SG or  β-actin primers,  and nuclease-free water to 20 l 
of final volume. A standard reference curve was performed in parallel 
using RNAs extracted from LAN5 cell line serially 1:2 diluited starting 
from 100 ng reaction to 3.125 ng.
 The thermal profile consisted of an initial activation step at 95°C 
for 15 minutes, followed by 45 cycles of 95°C for 10 seconds, 60°C 
for 15 seconds, 72°C for 15 seconds. Fluorescence in the FL1 channel 
was measured once per cycle at the end of the 72°C step. At the end 
of PCR cyccling,  a standard melting curve analysis was performed; 
briefly the amplicons were heated from 55°C to 95°C at 0.1°C/min 
with continuous fluorescence acquisition and as expected a single 
peak per amplicon was detected. Data were analysed using the relative 
quantification method of Pfaffl  with efficency correction, using  β-actin 
as normalization gene. 
Results
Mutational screening of the WFS1 gene (Table 1A, Figure 1B) 
revealed in the affected proband a “de novo” missense mutation in 
exon 5 (c.505 G>A) in heterozygous with an allele carrying 2 variations 
in exon 8: c.1332 C>G and c.1631C>G, both paternally inherited and 
never annotated before. c.1332 C>G  causes a premature STOP codon 
introduction at position 444 and c.1631C>G causes a substitution from 
a serine to a cysteine at position 544. The novel mutations were present 
both in the proband and his father; no mutation-caused disease was 
found in the other family members analysed (Figure 1A), strongly 
suggesting the paternal inheritance of c.1332 C>G and c.1631C>G 
mutations from a single allele and the “de novo” acquisition of the c.505 
G>A in the other allele of the proband. Many neutral polymorphisms 
were also detected in the proband (Table 1B).
As regards WFS1 expression, we found higher mRNA levels in the 
WS proband than in healthy subjects (5 children of the same age). The 
levels of WFS1 mRNA were also increased in the father (Figure 1C), 
In the present study we describe the clinical and molecular features 
of a novel WFS1 mutation carrying child and his family living in Sicily 
(Italy).
Methods
Patient and family history
Our study concerns a 12-year-old male, the younger of two 
children, with familial history of diabetes mellitus (both grandmothers 
and a paternal uncle with type 2 diabetes mellitus). No family member 
was suffering from psychiatric symptoms, visual disorders or hearing 
loss. The parents were healthy and non-consanguineous. All family 
members showed no signs of WS. The proband was diagnosed as 
affected by insulin-dependent diabetes mellitus without anti-Islet Cell 
Antibodies (ICA), antiGAD65 and Insulin-Autoantibodies (IAA), 
when he was 3 years old, with onset symptoms characterized by 
polyuria, polydipsia and ketosis. From the moment of diagnosis he was 
treated with basal-bolus insulin therapy, leading to poor control of his 
glycemic levels. He complained of vision decrease when he was 7 years 
old. Only at the age of 11 a visual examination was performed, including 
visual acuity determination and funduscopy. At examination, his visual 
acuity was 4/10 bilaterally and remained constant in subsequent years. 
Hypopigmentation with a waxy pallor of the optic disc was found in 
the macular area, so optical coherence tomography (OCT-Copernicus) 
was performed a few months later. The right and left optic nerve heads 
showed a cup-to-disc ratio of 0.557 and 0.551, respectively. A thickness 
reduction of the ganglion nerve fibres (mean values of 81 and 74 m in 
the right and left eye, respectively) and a reduced optic disc size (1.272 
and 1.506 mm2 in the right and left eye, respectively) were found. 
Some microhemorrhages in the macular area were also described. 
Retinal Fluorangiography (FAG) was normal in both eyes, with 
normal perimetry and Pattern Electroretinogram (PERG) amplitude. 
He showed a normal age-related, pubertal development assessed by 
the Tanner criteria (PH3G2) and a regular growth velocity. Dental 
examination only showed teeth discoloration. No gastrointestinal, 
psychiatric or neurological disorders and abnormalities of hearing 
function were reported by the parents. On the basis of the ocular 
characteristics WS was diagnosed.
DNA analysis 
Genomic DNA from peripheral blood of the proband and his 
family members was extracted using a commercially available kit 
(Qiagen, Hilden, Germany).
The 2-8 exons of WFS1 were amplified by PCR using sets of primers 
and conditions as previously published by Strom et al . PCR products 
were analyzed in agarose gels and subsequently amplified templates 
were purified with AMPure magnetic beads (Agencourt, Beckman-
Coulter) according to the manufacturer’s instructions and an aliquot of 
purified PCR product was cycle sequenced by the BigDye Terminator 
v3.1 Cycle Sequencing Kit (Applied Biosystems). These reactions were 
further processed by running a clean-up procedure with CleanSEQ 
beads (Agencourt, Beckman-Coulter) on a Biomek 3000 Laboratory 
automated workstation (Beckman-Coulter). Finally, the products were 
sequenced on a 3130XL Genetic Analyzer (Applied Biosystems). Wild-
type and mutated WFS1 sequences were compared manually.
RNA analysis
Total RNA samples were extracted by Ficoll-separated lymphocytes 
from the proband and his father along with a pool of lymphocytes from a 
control group matched for age and sex, using the RNeasy Mini Kit (Qiagen, 
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even if to a less degree, who is only an unaffected heterozygous mutant 
without evident WS phenotype.
Discussion
Genetic analyses in WS patients have identified a wide spectrum of 
mutations: many of them showed loss-of-function mutations such as 
stop, frame-shift and splice site mutations while missense mutations 
were detected in 35% of the cases. Different types of mutations located 
in the hydrophilic C-terminal part of the protein lead to complete 
and severe WS underlining the functional importance of Wolframin 
C-terminus [5,14,24-26]. 
Figure 1: A) The pedigree of family. The arrow points to the proband. B) WFS1 gene novel mutations in proband. Representative electropherograms from the 
affected patient show heterozygous mutations in exon 5 (505G>A) and in exon 8 (1332C>G; 1631C>G). C) qRT-PCR of WFS1 mRNA normalized expression 
against beta-actin in:
Column 1: Positive control LAN-5 cell line;
Column 2: Healthy subjects (mean values of 5 children);
Column 3: Proband;  
Column 4: Proband’s father.
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The diagnosis of Wolfram Syndrome is essentially clinical and 
mutation analysis is usually used to confirm diagnosis, though a recent 
update of WFS1 mutations revealed no obvious hot spots or clustering 
and mutations appeared to be distributed randomly within the entire 
coding sequence of the gene. The growing number of WS reports 
confirmed the wide spectrum of WFS1 mutations and the variations 
in phenotypes, fostering better understanding of the genotype-
phenotype correlation. Recent result highlighted the difficulties in 
a clear definition of the inclusion criteria; briefly WSF1 mutations 
have been clustered in three classes: type I, which lead to complete 
depletion of WFS1 protein due to the activation of nonsense-mediated 
decay, type II, which lead to complete degradation of WFS1 protein 
by keeping functional the degron in WFS1and type III, leading to the 
expression of a defective or shorter WFS1 protein. In some cases, optic 
atrophy and diabetes mellitus might not be the early manifestations 
of the clinical conditions in WS, and the age of onset and the disease 
progression might be correlated to the genotype of the affected 
individual; moreover, genotypic prevalence seems to exist in different 
geographical areas . It seems clear that the decline of β-cells population 
and activity is generally an early event in WS patients and that glucose 
toxicity enhances the ER stress-mediated progression of the disease.
In our study we describe the clinical and genetic features of a 
child with WS caused by a compound heterozygous mutations: a 
“de novo” missense mutation in exon 5 (previously reported as a 
causative mutation in a WFS family) in an allele and two novel not 
annotated mutations (c.1332 C>G; p.Y444X and c.1631 C>G; p.S544C) 
in exon 8. The two novel heterozygous changes in exon 8 were found 
in the proband and his father, pointing to the paternal inheritance 
of the mutations. Instead, the missense change E169K, was acquired 
sporadically in the proband, leading to the compound heterozygosis 
of the WFS1 gene and thus to the WF. The absence of clinical signs 
of the syndrome in the father and the severe WF phenotype in the 
child confirm these data. The missense mutation at exon 5 replaces 
a glutamic acid residue at position 169 with a lysine residue in the 
Wolframin extra reticular domain, while the paternally inherited 
nonsense mutation in exon 8 introduces a premature STOP codon at 
position 444 that disrupts part of the transmembrane domain. 
The Wolframin protein is expressed in many organs with the 
highest levels in the central nervous system, pancreas beta-cells, heart 
and muscle followed by the liver and lower levels in the kidney and 
spleen. However, in WS patients only selected populations of neuronal 
and endocrine cells are affected, probably the most affected by the 
impaired function of Wolframin [3,5,6,13,15]. The most probable 
mechanism is a hyper-activation of the ER stress system that leads in 
turn to cell death in susceptible cells. 
Interestingly, we found an unexpected higher mRNA levels in both 
the proband and to a less degree in his father than in healthy control 
subjects, although we were not able to detect Wolframin protein 
in our samples (data not shown). These data suggest that the lack of 
Wolframin activity could be due to the great instability of the mutants 
proteins instead of an increased turnover of the aberrant transcripts by 
the nonsense-mediated mRNA decay, as suggested by the classification 
reported in the genotypic classification of patients with Wolfram 
syndrome. Moreover, we can hazard that in the peripheral leukocytes 
of the proband, at least, a positive feedback mechanism increasing the 
WFS1 gene transcription could exist to compensate for the Wolframin 
deficit. 
In conclusions, our findings increase the spectrum of WFS1 
mutations in WS and reinforce the hypothesis of the existence of 
different WS phenotypes related to the different WFS1 mutations. 
Accordingly to the recent systematic review on the genotypic 
classification of patients with Wolfram syndrome , the “de novo” 
missense mutation isolated in exon 5 could be considered as a type II 
mutation which lead to complete degradation of WFS1 protein, while 
the mutations on exon 8 could be considered a type III mutation, 
leading to the expression of a shorter, readily degraded WFS1 protein.
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